Brentuximab Vedotin: A CD30-Directed Antibody-Cytotoxic Drug Conjugate-Reference-Cited by-同舟云学术

Brentuximab Vedotin: A CD30-Directed Antibody-Cytotoxic Drug Conjugate

Published:2013-01 Issue:1 Volume:33 Page:93-104
ISSN:0277-0008
Container-title:Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
language:en
Short-container-title:Pharmacotherapy

Author:

Newland Ashley M.¹²,Li Jenny X.³,Wasco Lindsey E.¹²,Aziz May T.¹²,Lowe Denise K.¹²

Affiliation:

1. Department of Pharmacy Services; Virginia Commonwealth University Health System/Medical College of Virginia Hospitals; Richmond Virginia

2. Virginia Commonwealth University School of Pharmacy; Richmond Virginia

3. Cedars-Sinai Medical Center; Los Angeles California

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/phar.1170/fullpdf

Reference49 articles.

1. National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology, hodgkin lymphoma (version 1.2012) http://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf

2. National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology, non-Hodgkin's lymphomas (version 1.2012) http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf

3. Howlader N Noone AM Krapcho M Surveillance Epidemiology and End Results (SEER) cancer statistics review, 1975-2008 Bethesda, MD National Cancer Institute http://seer.cancer.gov/csr/1975_2008/

4. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner;Hsu;Cancer Res,2006

5. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project;Savage;Blood,2008

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy;Cancers;2023-09-11

2. Drug development, Brazilian biodiversity and political choices: Where are we heading?;Journal of Toxicology and Environmental Health, Part B;2023-03-26

3. Drug targeting in anticancer chemotherapy;Medicinal Chemistry of Anticancer Drugs;2023

4. Novel Salvage Therapy Options for Initial Treatment of Relapsed/Refractory Classical Hodgkin’s Lymphoma: So Many Options, How to Choose?;Cancers;2022-07-20

5. CD30+ Lymphoproliferative Disorders as Potential Candidates for CD30-Targeted Therapies;Archives of Pathology & Laboratory Medicine;2022-03-17